Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials

Mellissa Hicks, Robert Wesolowski, Mahmoud Abdel‐Rasoul et al.|The Oncologist|2015

Cited by 48